Concepedia

Author

Cosimo Di Raimondo

University of Rome Tor VergataORCID

Also Known As

C. Di Raimondo, C. Raimondo, Cosimo DI RAIMONDO, Cosimo DI Raimondo, Cosimo Di Raimondo, Cosimo Di Raimondo, Di Raimondo, C.

64

Publications

772

Citations

18

H-Index

9

Concepts

All Affiliations

University of Rome Tor VergataPoliclinico Tor VergataCity of HopeUniversity of CataniaMagna Graecia University
CD

About

Cosimo Di Raimondo is an author at University of Rome Tor Vergata specializing in dermatology, medicine, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

92

2

Public Health

1

1

20

3

Environmental Health

1

1

20

4

Epidemiology

1

1

20

5

Cancer Epidemiology

1

1

20

Cosimo Di Raimondo

×

18

Publications

413

Citations

12

H-Index

YearCitations

Granulocyte-like myeloid derived suppressor cells (G-MDSC) are increased in multiple myeloma and are driven by dysfunctional mesenchymal stem cells (MSC)

Cesarina Giallongo, Daniele Tibullo, Nunziatina Laura Parrinello,

Oncotarget

2016

92

Clindamycin versus clindamycin plus rifampicin in hidradenitis suppurativa treatment: Clinical and ultrasound observations

Raffaele Dante Caposiena, Maria Vittoria Cannizzaro, Elisabetta Botti,

Journal of the American Academy of Dermatology

2018

72

Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis

Giulia Giovanardi, Andrea Chiricozzi, Luca Bianchi,

Dermatology

2018

32

Alexithymia affects patients with hidradenitis suppurativa

Andrea Chiricozzi, Giulia Giovanardi, Dante R Caposiena,

European Journal of Dermatology

2018

20

Expression of immune checkpoint molecules programmed death protein 1, programmed death‐ligand 1 and inducible T‐cell co‐stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome*

Cosimo Di Raimondo, Belén Rubio-González, Joycelynne Palmer,

British Journal of Dermatology

2022

20

Epidemiological and clinical analysis of exposure-related factors in non-melanoma skin cancer: A retrospective cohort study

Fabio Artosi, Gaetana Costanza, Monia Di Prete,

Environmental Research

2024

20

Long-Term Follow-Up for Q-Switched Nd:YAG Treatment of Nevus of Ota: Are High Number of Treatments Really Required? A Case Report

Ester Del Duca, Tiziano Zingoni, Luigi Bennardo,

Photobiomodulation Photomedicine and Laser Surgery

2020

19

MCAM/MUC18/CD146 as a Multifaceted Warning Marker of Melanoma Progression in Liquid Biopsy

Maria Cristina Rapanotti, Elisa Cugini, Marzia Nuccetelli,

International Journal of Molecular Sciences

2021

19

Bullous pemphigoid associated with cemiplimab therapy in a patient with locally advanced cutaneous squamous cell carcinoma

César A. Virgen, Tuyet A. Nguyen, Cosimo Di Raimondo,

JAAD Case Reports

2020

18

Salvage therapy with pegylated liposomal doxorubicin, bortezomib, cyclophosphamide, and dexamethasone in relapsed/refractory myeloma patients

Alessandra Romano, Annalisa Chiarenza, Concetta Conticello,

European Journal Of Haematology

2014

12

Page 1